Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, raised $20 million by offering 5 million shares at $4, as expected. At $4 per share, Pulse commands a diluted market cap of $51 million.
NovoCure (NVCR), which markets a wearable electric field device for brain cancer, raised $165 million at a $2.1 billion market cap in October 2015, but now trades -46% below its offer price.
Pulse Biosciences plans to list on the Nasdaq under the symbol PLSE. MDB Capital Group and Feltl and Company acted as lead managers on the deal.
